Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1992 2
1993 5
1994 2
1995 2
1996 2
1997 1
1998 7
1999 4
2000 3
2001 2
2003 1
2004 2
2005 2
2006 4
2007 4
2008 9
2009 5
2010 9
2011 8
2012 11
2013 7
2014 7
2015 3
2016 2
2017 2
2018 1
2021 2
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
Acute gefitinib-induced pneumonitis.
Ohyanagi F, Ando Y, Nagashima F, Narabayashi M, Sasaki Y. Ohyanagi F, et al. Among authors: narabayashi m. Int J Clin Oncol. 2004 Oct;9(5):406-9. doi: 10.1007/s10147-004-0418-0. Int J Clin Oncol. 2004. PMID: 15549594
Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer.
Kishi N, Matsuo Y, Shintani T, Ogura M, Mitsuyoshi T, Araki N, Fujii K, Okumura S, Nakamatsu K, Kishi T, Atsuta T, Sakamoto T, Ohtsu S, Katagiri T, Narabayashi M, Fujishiro S, Iizuka Y, Ozasa H, Hirai T, Mizowaki T; Kyoto Radiation Oncology Study Group (KROSG). Kishi N, et al. Among authors: narabayashi m. J Radiat Res. 2023 Jan 20;64(1):142-153. doi: 10.1093/jrr/rrac057. J Radiat Res. 2023. PMID: 36149029 Free PMC article.
Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non-Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab.
Shintani T, Kishi N, Matsuo Y, Ogura M, Mitsuyoshi T, Araki N, Fujii K, Okumura S, Nakamatsu K, Kishi T, Atsuta T, Sakamoto T, Narabayashi M, Ishida Y, Sakamoto M, Fujishiro S, Katagiri T, Kim YH, Mizowaki T. Shintani T, et al. Among authors: narabayashi m. Clin Lung Cancer. 2021 Sep;22(5):401-410. doi: 10.1016/j.cllc.2021.01.017. Epub 2021 Feb 4. Clin Lung Cancer. 2021. PMID: 33678582
Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.
Yamashita K, Nagashima F, Fujita K, Yamamoto W, Endo H, Miya T, Narabayashi M, Kawara K, Akiyama Y, Ando Y, Ando M, Sasaki Y. Yamashita K, et al. Among authors: narabayashi m. Jpn J Clin Oncol. 2011 Feb;41(2):204-9. doi: 10.1093/jjco/hyq197. Epub 2010 Oct 21. Jpn J Clin Oncol. 2011. PMID: 20965940 Clinical Trial.
Histopathological study of corpora amylacea pulmonum.
Dobashi M, Yuda F, Narabayashi M, Imai Y, Isoda N, Obata K, Umetsu A, Ohgushi M. Dobashi M, et al. Among authors: narabayashi m. Histol Histopathol. 1989 Apr;4(2):153-65. Histol Histopathol. 1989. PMID: 2485191
Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer.
Matsuo Y, Shibuya K, Nagata Y, Takayama K, Norihisa Y, Mizowaki T, Narabayashi M, Sakanaka K, Hiraoka M. Matsuo Y, et al. Among authors: narabayashi m. Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1104-11. doi: 10.1016/j.ijrobp.2009.12.022. Epub 2010 May 14. Int J Radiat Oncol Biol Phys. 2011. PMID: 20472343
97 results